We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Morphine-Like Synthetic Pain Killer Lacks Side Effects

By HospiMedica International staff writers
Posted on 06 Jun 2011
A team of pharmaceutical chemists has successfully synthesized conolidine, a rare natural product that is a potent analgesic as effective as morphine in alleviating inflammatory and acute pain, with few, if any, side effects.

Management of chronic pain is usually based on opioid analgesics despite the fact that they suffer from substantial liabilities that include addiction and tolerance, as well as depression of breathing, nausea, and chronic constipation.

In the current study investigators at the Scripps Research Institute (Jupiter, FL, USA) sought to develop a method for the synthesis of conolidine, a rare C5-nor stemmadenine natural product recently isolated from the stem bark of Tabernaemontana divaricata (a tropical flowering plant used in traditional Chinese, Ayurvedic, and Thai medicine). More...
Details of their research were published in the May 23, 2011, online edition of the journal Nature Chemistry.

"This was a classic problem in chemical synthesis," said Dr. Glenn Micalizio, associate professor in of chemistry at the Scripps Research Institute, "which we were able to solve effectively and efficiently--an achievement that made subsequent assessment of the potential therapeutic properties of this rare natural product possible."

The synthetic conolidine was tested in a mouse model of tonic and persistent pain. Results showed that the new synthetic compound suppressed acute pain and inflammatory-derived pain, two key measures of efficacy. The new compound passed easily through the blood-brain barrier, and was present in the brain and blood at relatively high concentrations up to four hours after injection.

"Pharmacological studies confirmed that while it is not an opiate, it is nearly as potent as morphine," said Dr. Micalizio.

Related Links:

Scripps Research Institute





Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.